Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges

Wang, Lifeng; Wang, Fusheng

doi:10.1007/s12072-019-09967-y

Cited by 34 publications

(24 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy, such as immune checkpoint inhibitors, has been shown to have effective antitumor effects. However, only a small percentage of people respond to immunotherapy (29,30). Although there have been some studies that have conducted immunophenotyping of the prognosis of HCC, some of the research models are not stable and some have the limitation of overfitting.…”

Section: Discussionmentioning

confidence: 99%

A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes

Zhang

Zheng

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world with a very poor prognosis. Immunotyping is of great significance for predicting HCC outcomes and guiding immunotherapy. Therefore, we sought to establish a reliable prognostic model for HBV-related HCC based on immune scores. We identified immune-related modules of The Cancer Genome Atlas LIHC and GSE14520 data sets through weighted gene co-expression network analysis and evaluated HCC through a non-negative matrix factorization algorithm. Through further bioinformatics analyses, we identified causes for prognostic differences between subtypes. The results illustrate a significant difference in prognosis based on immunotypes, which may stem from metabolic disorders and increased tumor invasion associated with the high expression of genes related to stem cell characteristics. In conclusion, we identified a novel HBV-related HCC immune subtype and determined its immunological characteristics, which provides ideas for further individualized immunotherapy research.

show abstract

Section: Discussionmentioning

confidence: 99%

A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes

Zhang

Zheng

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…HCC is associated with inflammation and a suppressed immune environment, making CIT approaches a rational therapeutic approach (180)(181)(182)(183). Encouraging early clinical data from two single-arm trials of pembrolizumab and nivolumab in advanced HCC formed the basis for the accelerated approval by the FDA (184,185).…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

Hack¹,

Zhu

Wang³

2020

Front. Immunol.

183

132

View full text Add to dashboard Cite

show abstract

“…To some extent, these checkpoints enhance antitumor immunity as well as exaggerate immune system activation ( 17 ). Among the available inhibitors, PD-1 inhibitors are currently thought to be the most promising ( 18 – 20 ). Based on two phase II clinical trials, CheckMate 040 and KEYNOTE-224 in which both nivolumab and pembrolizumab yielded promising results as second line agents after first-line sorafenib treatment ( 21 , 22 ), the Food and Drug Administration (FDA) approved nivolumab in 2017 and pembrolizumab in 2018 as second-line therapies for HCC ( 23 , 24 ).…”

Section: Introductionmentioning

confidence: 99%

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)

2020

View full text Add to dashboard Cite

In recent years, the incidence of liver cancer has increased and is currently the sixth most common tumor and the second leading cause of cancer-associated mortality worldwide. Most cases of liver cancer are hepatocellular carcinoma (HCC). Surgery, including liver transplantation or resection, and radiofrequency ablation therapies are all considered to be the curative treatment options for early-stage HCC. However, most patients have advanced HCC at the time of diagnosis, contributing to a poor prognosis. Therefore, improved treatment for late-stage HCC is needed. Immune checkpoint inhibitors (ICIs), among which programmed death receptor 1 (PD-1)/PD-ligand 1 and cytotoxic T lymphocyte-associated protein 4 are the representative immunological checkpoints, have shown great promise and progress for HCC treatment. The present review summarizes recent studies that have focused on ICIs and discusses the present limitations affecting the development of new therapeutic strategies.

show abstract

Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges

Cited by 34 publications

References 76 publications

A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes

A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)

Contact Info

Product

Resources

About